Tirzepatide Tops Semaglutide for Weight Loss in Head-to-Head Trial, Eli Lilly Says
Those treated with tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, lost on average 50.3 lb (22.8 kg) while those treated with semaglutide lost 33.1 lb (15 kg), translating to a 47% greater relative weight loss with tirzepatide.
LILLY'S TIRZEPATIDE SUPERIOR TO WEGOVY® (SEMAGLUTIDE) IN HEAD-TO-HEAD TRIAL SHOWING AN AVERAGE WEIGHT LOSS OF 20.2% VS. 13.7%
Eli Lilly Canada today announced topline results from the SURMOUNT-5 Phase 3b open-label randomized clinical trial. Tirzepatide provided a 47% greater relative weight loss compared to Wegovy® (semaglutide).
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.
One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...
The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible ...
The trial enrolled 751 adults with obesity or overweight conditions and at least one weight-related medical problem ...
Brand companies who own GLP-1 products have been pushing the Food and Drug Administration (FDA) to limit their compounding. On August 28, 2024, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback